HUMAN FC RECEPTOR--ENHANCED ANTIGEN PRESENTATION DEFINED
HUMAN FC RECEPTOR--ENHANCED ANTIGEN PRESENTATION DEFINED
批准号:
2517242
负责人:
Edmund J Gosselin
金额:
$11.55万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1993
资助国家:
美国
项目状态:
已结题
起止时间:
1993-09-01 至 2000-08-31
关键词:
B lymphocyte T lymphocyte antibody receptor antigen antibody reaction antigen presentation antireceptor antibody chimeric proteins dendritic cells electron microscopy flow cytometry human tissue immunocytochemistry immunoglobulin A immunoglobulin G interferon gamma intracellular transport lymphocyte proliferation macrophage monoclonal antibody monocyte nitrophenol protein transport tissue /cell culture
中文摘要
点击翻译按钮获取中文摘要
英文摘要
The guiding hypotheses for this proposal are that enhancement of antigen
(Ag) presentation through the interaction of Ag, antibody (Ab) and Fc
receptors (FcR): 1) will stimulate active immunity to immunogens, and 2)
will vary dependent on the type of FcR or the human Ab isotope involved.
FcR-mediated uptake of Ag-Ab complexes can enhance Ag presentation by
monocytes at least 100-fold. In addition, recent studies suggest that
directing Ag to FcR in vivo may bring out substantial increases in the
effectiveness of vaccines. Specific Aim 1 will be to determine which FcR
types are most effective at enhancing Ag presentation by monocytes. This
will be done by attaching Ag to (Fab')2 or Fab monoclonal Ab (mAb)
specific for human FcgammaRI, FCgammaRII, FcgammaRIII (the FcR for IgG)
or FcalphaR (the FcR for IgA). Assays will consist of varying numbers
of Ag presenting cells, Ag-specific T cells, Ag alone, Ab alone or Ag-Ab
conjugates. T cell proliferation and lymphokine production by T cells
will be used to measure Ag presentation.
Depending on the infectious agent or immunogen involved, the isotope of
human Ab produced will vary. Specific Aim 2 will be to define the
ability of all human IgG isotopes, and IgA, to participate in enhanced
Ag presentation. The hapten NP will be linked to the Ag. Human Fc mouse
Fab anti-NP chimeric Ab will be used to create Ag-Ab complexes. Chimeric
Ab composed of each of the human IgG isotopes is available and the ratio
of NP to Ag will be varied to vary the size of the complex. FcR type-
specific mAb will be used as blocking agents to confirm which FcR are
being utilized during FcR-enhanced Ag presentation.
Human monocytes, macrophages and B cells all express one or more forms
of FcR. In addition, B cells have surface immunoglobulin (Ig) which
binds Ag and thereby also enhances Ag uptake and subsequent presentation.
Dendritic cells are considered to be an important Ag presenting cell as
well, although they do not appear to express FcgammaR on their surface.
Specific Aim 3 will be to compare the efficiency of receptor-enhanced and
non-enhanced Ag presentation among these cell types.
These studies will not only improve our understanding of the normal
immune response, but will also provide novel approaches for enhancing the
effectiveness of vaccines.
期刊论文(8)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Production of genetically engineered biotinylated interleukin-2 and its application in a rapid nonradioactive assay for T-cell activation.
基因工程生物素化白细胞介素 2 的生产及其在 T 细胞激活快速非放射性测定中的应用。
DOI:
10.1128/cdli.10.3.339-344.2003
发表时间:
2003
期刊:
Clinical and diagnostic laboratory immunology
影响因子:
--
作者:
[Jordan,RobertA, Preissler,MarkT, Banas,JeffreyA, Gosselin,EdmundJ]
通讯作者:
Gosselin,EdmundJ
Inhibition of interleukin-2 by a Gram-positive bacterium, Streptococcus mutans.
革兰氏阳性菌变形链球菌对白细胞介素 2 的抑制作用。
DOI:
10.1046/j.1365-2567.1998.00631.x
发表时间:
1998
期刊:
Immunology
影响因子:
6.4
作者:
[Plitnick,LM, Banas,JA, Jelley-Gibbs,DM, O'neil,J, Christian,T, Mudzinski,SP, Gosselin,EJ]
通讯作者:
Gosselin,EJ
Expression of HLA-DR (major histocompatibility complex class II) on neutrophils from patients treated with granulocyte-macrophage colony-stimulating factor for mobilization of stem cells.
使用粒细胞巨噬细胞集落刺激因子动员干细胞的患者的中性粒细胞上 HLA-DR(主要组织相容性复合物 II 类)的表达。
DOI:
--
发表时间:
1995
期刊:
Blood
影响因子:
20.3
作者:
[Mudzinski,SP, Christian,TP, Guo,TL, Cirenza,E, Hazlett,KR, Gosselin,EJ]
通讯作者:
Gosselin,EJ
Stealth cells: prevention of major histocompatibility complex class II-mediated T-cell activation by cell surface modification.
隐形细胞:通过细胞表面修饰来预防 II 类主要组织相容性复合物介导的 T 细胞激活。
DOI:
--
发表时间:
1999
期刊:
Blood
影响因子:
20.3
作者:
[Murad,KL, Gosselin,EJ, Eaton,JW, Scott,MD]
通讯作者:
Scott,MD
Use of Nramp2-transfected Chinese hamster ovary cells and reticulocytes from mk/mk mice to study iron transport mechanisms.
使用 Nramp2 转染的中国仓鼠卵巢细胞和 mk/mk 小鼠的网织红细胞研究铁转运机制。
DOI:
10.1016/j.exphem.2008.04.014
发表时间:
2008
期刊:
Experimental hematology
影响因子:
2.6
作者:
[Zhang,An-Sheng, Canonne-Hergaux,Francois, Gruenheid,Samantha, Gros,Philippe, Ponka,Prem]
通讯作者:
Ponka,Prem
共 7 条
An Adjuvant-Independent Dual-Targeted (Multi-Function) Mucosal Vaccine Platform
-
批准号:8911997
-
项目类别:
-
资助金额:$21.88万
-
财政年份:2015
-
负责人:Edmund J Gosselin
-
依托单位:
Criteria-Directed Vaccine Generation Via Ag Mimicry, Adjuvancy, And APC-Targeting
-
批准号:9300826
-
项目类别:
-
资助金额:$58.4万
-
财政年份:2013
-
负责人:Edmund J Gosselin
-
依托单位:
Criteria-Directed Vaccine Generation Via Ag Mimicry, Adjuvancy, And APC-Targeting
-
批准号:8443445
-
项目类别:
-
资助金额:$58.4万
-
财政年份:2013
-
负责人:Edmund J Gosselin
-
依托单位:
Criteria-Directed Vaccine Generation Via Ag Mimicry, Adjuvancy, And APC-Targeting
-
批准号:8698271
-
项目类别:
-
资助金额:$58.4万
-
财政年份:2013
-
负责人:Edmund J Gosselin
-
依托单位:
Mechanisms Involved in, and Development of, FcR-Enhanced Mucosal Vaccination
-
批准号:8261081
-
项目类别:
-
资助金额:$38.47万
-
财政年份:2009
-
负责人:Edmund J Gosselin
-
依托单位:
Mechanisms Involved in, and Development of, FcR-Enhanced Mucosal Vaccination
-
批准号:7807054
-
项目类别:
-
资助金额:$38.86万
-
财政年份:2009
-
负责人:Edmund J Gosselin
-
依托单位:
Mechanisms Involved in, and Development of, FcR-Enhanced Mucosal Vaccination
-
批准号:7660124
-
项目类别:
-
资助金额:$37.83万
-
财政年份:2009
-
负责人:Edmund J Gosselin
-
依托单位:
Mechanisms Involved in, and Development of, FcR-Enhanced Mucosal Vaccination
-
批准号:8049731
-
项目类别:
-
资助金额:$38.47万
-
财政年份:2009
-
负责人:Edmund J Gosselin
-
依托单位:
Protective Activity of a Multi-Functional Immunogen
-
批准号:7195315
-
项目类别:
-
资助金额:$19.75万
-
财政年份:2007
-
负责人:Edmund J Gosselin
-
依托单位:
Protective Activity of a Multi-Functional Immunogen
-
批准号:7350212
-
项目类别:
-
资助金额:$22.45万
-
财政年份:2007
-
负责人:Edmund J Gosselin
-
依托单位:
ENHANCED T AND B CELL RESPONSES VIA RECOMBINANT PROTEINS
-
批准号:6213323
-
项目类别:
-
资助金额:$23.25万
-
财政年份:2000
-
负责人:Edmund J Gosselin
-
依托单位:
ENHANCED T AND B CELL RESPONSES VIA RECOMBINANT PROTEINS
-
批准号:6374417
-
项目类别:
-
资助金额:$23.25万
-
财政年份:2000
-
负责人:Edmund J Gosselin
-
依托单位:
TWO COMPONENT STRATEGY FOR IMMUNE TARGETING
-
批准号:2642824
-
项目类别:
-
资助金额:$10.0万
-
财政年份:1998
-
负责人:Edmund J Gosselin
-
依托单位:
HUMAN FC RECEPTOR--ENHANCED ANTIGEN PRESENTATION DEFINED
-
批准号:2070930
-
项目类别:
-
资助金额:$10.71万
-
财政年份:1993
-
负责人:Edmund J Gosselin
-
依托单位:
HUMAN FC RECEPTOR--ENHANCED ANTIGEN PRESENTATION DEFINED
-
批准号:2070929
-
项目类别:
-
资助金额:$9.82万
-
财政年份:1993
-
负责人:Edmund J Gosselin
-
依托单位:
HUMAN FC RECEPTOR--ENHANCED ANTIGEN PRESENTATION DEFINED
-
批准号:3456540
-
项目类别:
-
资助金额:$9.84万
-
财政年份:1993
-
负责人:Edmund J Gosselin
-
依托单位:
HUMAN FC RECEPTOR--ENHANCED ANTIGEN PRESENTATION DEFINED
-
批准号:2070931
-
项目类别:
-
资助金额:$11.12万
-
财政年份:1993
-
负责人:Edmund J Gosselin
-
依托单位:
Immunology Core
-
批准号:8698578
-
项目类别:
-
资助金额:$23.77万
-
财政年份:--
-
负责人:Edmund J Gosselin
-
依托单位:
Immunology Core
-
批准号:8711178
-
项目类别:
-
资助金额:$21.43万
-
财政年份:--
-
负责人:Edmund J Gosselin
-
依托单位:
Redox Control of F. tularensis Pathogenesis
-
批准号:8711175
-
项目类别:
-
资助金额:$42.55万
-
财政年份:--
-
负责人:Edmund J Gosselin
-
依托单位:
海外基金